Search
Atractylodes lancea root oil
go.drugbank.com/drugs/DB14338ApprovedAtractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: OHUI White Extreme Illuminating Pact No.10, OHUI White Extreme Illuminating Pact No.10Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalPatients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)
Prezatide
go.drugbank.com/drugs/DB11296ApprovedPrezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113]
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation … and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs Used in Benign Prostatic Hypertrophy, Drugs for Urinary Frequency and IncontinenceLamivudine
go.drugbank.com/drugs/DB00709ApprovedInvestigationalIt is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). … A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring.
Mixtures: N/A, N/ACategories: Antivirals used in combination for the treatment of HIV infections, Antivirals for Systemic UseImipramine
go.drugbank.com/drugs/DB00458ApprovedInvestigationalThey contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. … Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label].
Synonyms: 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine, N-(γ-dimethylaminopropyl)iminodibenzylCategories: Antidepressive Agents Indicated for Depression, Non-Selective Monoamine Reuptake InhibitorsDichloroacetic acid
go.drugbank.com/drugs/DB08809ApprovedInvestigationalWithdrawnA phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market